{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:06:51Z","timestamp":1789538811322,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s41669-024-00503-9","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:02:30Z","timestamp":1718877750000},"page":"651-664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-8547","authenticated-orcid":false,"given":"Diana Beatriz","family":"Bayani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao Clement","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-2226","authenticated-orcid":false,"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa G.","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-7229","authenticated-orcid":false,"given":"Allison Ching Yee","family":"Tso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-0440","authenticated-orcid":false,"given":"John","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-1801","authenticated-orcid":false,"given":"Hwee Lin","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"503_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","volume":"2","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Value and cost of myeloma therapy. Am Soc Clin Oncol Educ Book. 2018;2:662\u20136.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"503_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221\u20137.","journal-title":"JAMA Oncol"},{"key":"503_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up<sup>\u2020<\/sup>. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"503_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"18","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1685\u2013717.","journal-title":"J Natl Compr Canc Netw"},{"key":"503_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.11622\/smedj.2016150","volume":"58","author":"S de Mel","year":"2017","unstructured":"de Mel S, Chen Y, Gopalakrishnan SK, et al. The Singapore myeloma study group consensus guidelines for the management of patients with multiple myeloma. Singapore Med J. 2017;58:55\u201371.","journal-title":"Singapore Med J"},{"key":"503_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.","journal-title":"Blood Cancer J"},{"key":"503_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582\u201396.","journal-title":"Lancet Oncol"},{"key":"503_CR9","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"503_CR10","unstructured":"Agency for Care Effectiveness. Daratumumab-based regimens for newly diagnosed multiple myeloma. Technology Guidance from the MOH Drug Advisory Committee. Singapore, 2022."},{"key":"503_CR11","doi-asserted-by":"publisher","first-page":"204062071989487","DOI":"10.1177\/2040620719894871","volume":"10","author":"N Abdallah","year":"2019","unstructured":"Abdallah N, Kumar SK. Daratumumab in untreated newly diagnosed multiple myeloma. Ther Adv Hematol. 2019;10:2040620719894871.","journal-title":"Ther Adv Hematol."},{"key":"503_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20:1087.","journal-title":"BMC Cancer"},{"key":"503_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1186\/s12885-021-08881-7","volume":"21","author":"S Atrash","year":"2021","unstructured":"Atrash S, Thompson-Leduc P, Tai MH, et al. Treatment patterns and effectiveness of patients with multiple myeloma initiating daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer. 2021;21:1207.","journal-title":"BMC Cancer"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood-2021-144914","volume":"138","author":"R Fonseca","year":"2021","unstructured":"Fonseca R, Facon T, Hashim M, et al. First-Line use of daratumumab, lenalidomide, and dexamethasone confers survival benefit compared with second-line use of daratumumab-based regimens in transplant-ineligible patients with multiple myeloma: analysis of different clinical scenarios. Blood. 2021;138:118.","journal-title":"Blood"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_100028","volume":"41","author":"NB Leighl","year":"2021","unstructured":"Leighl NB, Nirmalakumar S, Ezeife DA, et al. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021;41:1\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"503_CR16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40261-020-00972-w","volume":"40","author":"AE Kim","year":"2020","unstructured":"Kim AE, Choi DH, Chang J, et al. Performance-based risk-sharing arrangements (PBRSA): is it a solution to increase bang for the buck for pharmaceutical reimbursement strategy for our nation and around the world? Clin Drug Investig. 2020;40:1107\u201313.","journal-title":"Clin Drug Investig"},{"key":"503_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","volume":"87","author":"M Siddiqui","year":"2012","unstructured":"Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87:935\u201343.","journal-title":"Mayo Clin Proc"},{"key":"503_CR18","doi-asserted-by":"publisher","first-page":"e212026","DOI":"10.1001\/jamaoncol.2021.2026","volume":"7","author":"KN Vokinger","year":"2021","unstructured":"Vokinger KN, Hwang TJ, Daniore P, et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 2021;7:e212026\u2013126.","journal-title":"JAMA Oncol"},{"key":"503_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s40273-017-0535-z","volume":"35","author":"JJ Carlson","year":"2017","unstructured":"Carlson JJ, Chen S, Garrison LP Jr. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017;35:1063\u201372.","journal-title":"Pharmacoeconomics"},{"key":"503_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","volume":"16","author":"LP Garrison Jr","year":"2013","unstructured":"Garrison LP Jr, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16:703\u201319.","journal-title":"Value Health."},{"key":"503_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2020-136896","volume":"136","author":"K Huynh","year":"2020","unstructured":"Huynh K, Aoki N, Kim K, et al. The Asia-Pacific Myeloma and Related Diseases Registry: preliminary results of real-world treatment patterns and clinical outcomes. Blood. 2020;136:30\u20131.","journal-title":"Blood"},{"key":"503_CR22","unstructured":"Singapore DoS. Complete life tables for Singapore resident population, 2021\u20132022. 2022."},{"key":"503_CR23","unstructured":"Procedures and guidelines for company submissions to the Agency for Care Effectiveness for funding consideration. Singapore: Agency for Care Effectiveness, 2022."},{"key":"503_CR24","unstructured":"Drug and Vaccine Evaluation Methods and Process Guide. Singapore: Agency for Care Effectiveness, 2021."},{"key":"503_CR25","unstructured":"Woods B, Sideris E, Palmer S, et al. Nice DSU Technical Support Document 19: partitioned survival analysis for decision modelling in health care: a critical review. Report By The Decision Support Unit. NICE Decision Support Unit, 2017."},{"key":"503_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14737167.2022.2017285","volume":"22","author":"XY Wong","year":"2022","unstructured":"Wong XY, Chng WJ, Aziz MIA, et al. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and\/or refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2022;22:207\u201315.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"503_CR27","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"503_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"503_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2021-000094","volume":"1","author":"NR Latimer","year":"2022","unstructured":"Latimer NR, Adler AI. Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness. BMJ Med. 2022;1: e000094.","journal-title":"BMJ Med"},{"key":"503_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jha2.798","volume":"4","author":"DB Bayani","year":"2023","unstructured":"Bayani DB, Lin YC, Ooi MG, et al. Real-world utilization and healthcare costs for multiple myeloma: a retrospective analysis of patients in Singapore. eJHaem. 2023;4:2.","journal-title":"eJHaem."},{"key":"503_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/0269216321999576","volume":"35","author":"B Doble","year":"2021","unstructured":"Doble B, Wong WHM, Finkelstein E. End-of-life cost trajectories and the trade-off between treatment costs and life-extension: findings from the cost and medical care of patients with advanced serious illness (COMPASS) cohort study. Palliat Med. 2021;35:893\u2013903.","journal-title":"Palliat Med"},{"key":"503_CR32","unstructured":"XE. Convert US dollars to singapore dollars. XE. 2023."},{"key":"503_CR33","unstructured":"Singapore healthcare resource sheet. In: Agency for Care Effectiveness, ed. Singapore, 2023."},{"key":"503_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood.V126.23.25.25","volume":"126","author":"B Durie","year":"2015","unstructured":"Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood. 2015;126:25.","journal-title":"Blood"},{"key":"503_CR35","first-page":"29","volume":"24","author":"JJ Carlson","year":"2018","unstructured":"Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018;24:29\u201338.","journal-title":"J Manag Care Spec Pharm"},{"key":"503_CR36","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","volume":"19","author":"AJ Jakubowiak","year":"2016","unstructured":"Jakubowiak AJ, Campioni M, Benedict \u00c1, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016;19:1061\u201374.","journal-title":"J Med Econ"},{"key":"503_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.HS9.0000936164.84357.ed","volume":"7","author":"K Weisel","year":"2023","unstructured":"Weisel K, Kumar S, Moreau P, et al. P09 Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (Ndmm): updated analysis of the phase 3 Maia study. Hemasphere. 2023;7:2.","journal-title":"Hemasphere."},{"key":"503_CR38","doi-asserted-by":"publisher","first-page":"10150","DOI":"10.1182\/blood-2022-163335","volume":"140","author":"SK Kumar","year":"2022","unstructured":"Kumar SK, Moreau P, Bahlis NJ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Maia study. Blood. 2022;140:10150\u20133.","journal-title":"Blood"},{"key":"503_CR39","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95:1486\u201394.","journal-title":"Am J Hematol"},{"key":"503_CR40","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40273-017-0562-9","volume":"35","author":"SE Grimm","year":"2017","unstructured":"Grimm SE, Strong M, Brennan A, et al. The HTA risk analysis chart: visualising the need for and potential value of managed entry agreements in health technology assessment. Pharmacoeconomics. 2017;35:1287\u201396.","journal-title":"Pharmacoeconomics"},{"key":"503_CR41","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462324000217","volume":"40","author":"DB Bayani","year":"2024","unstructured":"Bayani DB, Wee HL. Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders\u2019 perspectives. Int J Technol Assess Health Care. 2024;40: e22.","journal-title":"Int J Technol Assess Health Care"},{"key":"503_CR42","unstructured":"Grimm S, Strong M, Brennan A, et al. Framework for analysing risk in health technology assessments and its application to managed entry agreements. Decision Support Unit, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA 2016."},{"key":"503_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989X13505910","volume":"34","author":"M Strong","year":"2014","unstructured":"Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. Med Decis Making. 2014;34:311\u201326.","journal-title":"Med Decis Making"},{"key":"503_CR44","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/0272989X07302555","volume":"27","author":"A Brennan","year":"2007","unstructured":"Brennan A, Kharroubi S, O\u2019Hagan A, et al. Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Med Decis Making. 2007;27:448\u201370.","journal-title":"Med Decis Making"},{"key":"503_CR45","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.20.01849","volume":"39","author":"KK Patel","year":"2021","unstructured":"Patel KK, Giri S, Parker TL, et al. Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. J Clin Oncol. 2021;39:1119\u201328.","journal-title":"J Clin Oncol"},{"key":"503_CR46","first-page":"1691","volume":"27","author":"N Narsipur","year":"2021","unstructured":"Narsipur N, Bulla S, Yoo C, et al. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Manag Care Spec Pharm. 2021;27:1691\u2013702.","journal-title":"J Manag Care Spec Pharm"},{"key":"503_CR47","unstructured":"National Institute for Health and Care Excellence. Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. 2023."},{"key":"503_CR48","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.1200\/JCO.2023.41.16_suppl.8037","volume":"41","author":"BG Durie","year":"2023","unstructured":"Durie BG, Kumar S, Ammann EM, et al. Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. J Clin Oncol. 2023;41:8037\u2013137.","journal-title":"J Clin Oncol"},{"key":"503_CR49","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2023-180829","volume":"142","author":"L Gordan","year":"2023","unstructured":"Gordan L, Medhekar R, Fu AZ, et al. Systematic literature review and meta-analysis of comparative clinical evidence investigating daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) as first-line treatment for transplant-ineligible newly diagnosed multiple myeloma. Blood. 2023;142:1963.","journal-title":"Blood"},{"key":"503_CR50","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1093\/oncolo\/oyad053","volume":"28","author":"R Fonseca","year":"2023","unstructured":"Fonseca R, Facon T, Hashim M, et al. Impact of treatment sequencing on overall survival in patients with transplant-ineligible newly diagnosed myeloma. Oncologist. 2023;28:e263\u20139.","journal-title":"Oncologist"},{"key":"503_CR51","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, et al. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23:1613\u201321.","journal-title":"Value Health."},{"key":"503_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jval.2021.09.011","volume":"25","author":"I Majer","year":"2022","unstructured":"Majer I, Kroep S, Maroun R, et al. Estimating and extrapolating survival using a state-transition modeling approach: a practical application in multiple myeloma. Value Health. 2022;25:595\u2013604.","journal-title":"Value Health."},{"key":"503_CR53","doi-asserted-by":"publisher","first-page":"e218084","DOI":"10.1001\/jamanetworkopen.2021.8084","volume":"4","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Koehn K, Abdallah A-O, et al. Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review. JAMA Netw Open. 2021;4:e218084\u2013184.","journal-title":"JAMA Netw Open"},{"key":"503_CR54","unstructured":"National Institute for Health and Care Excellence. Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014]. 2023."},{"key":"503_CR55","unstructured":"Loh L. Assistance available for cancer patients who need medications not on new list. 2022."},{"key":"503_CR56","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40273-021-01060-3","volume":"39","author":"SE Grimm","year":"2021","unstructured":"Grimm SE, Pouwels X, Ramaekers BLT, et al. State of the ART? Two new tools for risk communication in health technology assessments. Pharmacoeconomics. 2021;39:1185\u201396.","journal-title":"Pharmacoeconomics"},{"key":"503_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-019-00855-9","volume":"38","author":"SE Grimm","year":"2020","unstructured":"Grimm SE, Pouwels X, Ramaekers BLT, et al. Development and validation of the Transparent Uncertainty Assessment (TRUST) tool for assessing uncertainties in health economic decision models. Pharmacoeconomics. 2020;38:205\u201316.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00503-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T08:08:41Z","timestamp":1724918921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00503-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00503-9","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"3 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.B. is a recipient of a Ph.D. Research Scholarship from the National University of Singapore. The rest of the authors received no support for the research, authorship, and publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.C. has been a member of the Myeloma UK Access Advisory Group since 2021 advising on HTA. This is an unpaid role for the patient charity. The rest of the authors have no conflicts to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study received ethics approval from the Domain Specific Review Board (DSRB) of the National Healthcare Group in Singapore (DSRB Reference: 2021-00038).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study used data obtained from the Yale University Open Data Access Project, which has an agreement with Janssen Research & Development, L.L.C. The interpretation and reporting of research using this data are solely the responsibility of the authors and does not necessarily represent the official views of the Yale University Open Data Access Project or Janssen Research & Development, L.L.C.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The R codes used in this study are available on GitHub ().","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"D.B. conceptualized the study, reviewed the literature, performed the analyses, and drafted the manuscript. C.N., A.T., M.O., and L.Y.C. assisted with data acquisition and management and contributed to the study design and manuscript preparation. J.C. and W.H.L. reviewed the analysis and findings. D.B. drafted the manuscript, and all authors reviewed, edited, and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}